Fluidigm Corporation (NASDAQ:FLDM) CEO Stephen Christopher Linthwaite bought 45,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was acquired at an average cost of $2.66 per share, for a total transaction of $119,700.00. Following the completion of the transaction, the chief executive officer now owns 106,977 shares in the company, valued at $284,558.82. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Fluidigm Corporation (NASDAQ FLDM) traded up 14.02% during midday trading on Tuesday, hitting $3.09. The company had a trading volume of 873,968 shares. Fluidigm Corporation has a one year low of $2.52 and a one year high of $9.65. The company’s market cap is $90.52 million. The company’s 50 day moving average is $3.84 and its 200-day moving average is $5.08.

Fluidigm Corporation (NASDAQ:FLDM) last released its earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.02. The firm had revenue of $23.90 million for the quarter, compared to analyst estimates of $23.50 million. Fluidigm Corporation had a negative return on equity of 104.38% and a negative net margin of 74.05%. The company’s revenue was down 15.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.63) EPS. On average, equities analysts predict that Fluidigm Corporation will post ($2.19) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Fluidigm Corporation (FLDM) CEO Acquires 45,000 Shares of Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/insider-buying-fluidigm-corporation-fldm-ceo-acquires-45000-shares-of-stock.html.

Hedge funds have recently made changes to their positions in the company. American International Group Inc. increased its stake in shares of Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock worth $102,000 after buying an additional 1,187 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Fluidigm Corporation during the fourth quarter worth approximately $119,000. Stoneridge Investment Partners LLC increased its stake in shares of Fluidigm Corporation by 4.2% in the first quarter. Stoneridge Investment Partners LLC now owns 25,293 shares of the medical research company’s stock worth $144,000 after buying an additional 1,013 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Fluidigm Corporation by 15.0% in the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock worth $146,000 after buying an additional 3,327 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its stake in shares of Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock worth $151,000 after buying an additional 632 shares in the last quarter. Institutional investors own 91.66% of the company’s stock.

A number of equities analysts have issued reports on FLDM shares. Zacks Investment Research raised Fluidigm Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 1st. ValuEngine lowered Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.